Patent Expiry and Pharmaceutical Market Opportunities at the Nexus of Pricing and Innovation Policy
48 Pages Posted: 5 Oct 2012
Date Written: October 3, 2012
Abstract
This paper explores the academic literature and empirical evidence associated with the strategic and tactical opportunities available to pharmaceutical firms confronted with the loss of patent protection on their branded drug. The marketing dimensions of product innovation, pricing and brand equity options are considered together with exclusivity options available through government regulators such as the US Food and Drug Administration. These options are then considered in the context of the legal monopolies available to innovators through the policy lenses of intellectual property. This paper further explores the maxim that sustainable competitive advantage for pharmaceutical innovators is realized at the nexus of marketing choices, intellectual property and regulatory regimes. Separate examples in gastro intestinal and neurological medications will be used to explore how the various options might be integrated together and used in a time sequenced, longitudinal manner to extend the market advantages and earnings levels of the original pharmaceutical compound innovation. Areas of potentially fruitful future academic research are described.
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
The Effect of Prescription Drug Advertising on Doctor Visits
By Toshiaki Iizuka and Ginger Zhe Jin
-
Direct to Consumer Advertising and Prescription Choice
By Toshiaki Iizuka and Ginger Zhe Jin
-
Direct-to-Consumer Advertising in Pharmaceutical Markets
By Kurt Richard Brekke and Michael Kuhn
-
By Rosemary J. Avery, Donald Kenkel, ...
-
Drug Advertising and Health Habit
By Toshiaki Iizuka and Ginger Zhe Jin
-
The Cost Effectiveness of Direct to Consumer Advertising for Prescription Drugs
By Paul H. Rubin and Adam Atherly
-
Mitigating Agency Problems by Advertising, with Special Reference to Managed Health Care
By Paul H. Rubin and Joel L. Schrag